San
Francisco, Nov 27 The global gene
therapy market size is expected to reach USD 39.54 million by
2026. Rising competition among manufacturers and high number of molecules in
pipeline are supporting the growth of the market.
Gene therapy
development is aimed to cure rare diseases and even some hereditary diseases,
which are caused by a mutated or faulty gene. Moreover, ever-increasing need
for new cures for orphan diseases and rising incidence of cancer caused due to
mutations in genes are likely to stir up the demand for gene therapy.
As of early 2016, there
were more than 1000 molecules in the pipeline in various clinical phases.
However, around 76.0% of the molecules are in the developmental or preclinical
stages and expected to hit the market in late 2020’s.
A great number of large
pharma/biotech players are estimated to acquire small firms as many have been
trying to develop in-house expertise and build their own pipelines. This trend
is anticipated to help the market gain tremendous traction over the coming
years. Combination of gene therapy with small molecules or protein therapy is
said to have lesser side effects and better efficacy as compared to gene
therapy alone.
Cancer held the
dominant share in the market in 2017 owing to relatively high adoption of gene
therapies for cancer treatment. Continual rise in new cancer cases and related
mortality per year triggers the need for development of robust treatment
options. Ongoing developments in cancer gene studies have provided significant
information about cancer-related molecular signatures, which in turn, is
projected to support ongoing clinical trials for cancer therapeutics
Browse full research report on Gene
Therapy Market:
www.grandviewresearch.com/industry-analysis/gene-therapy-market
Further Key
Findings from the Study Suggest:
- More than 60.0% of the market is
occupied by cancer research owing to a large pipeline.
- Adenoviral vectors are the most
used in pipeline development, closely followed by retroviral vectors.
- Europe and the U.S. are poised to
occupy the largest cumulative share in the market throughout the forecast
period.
- Asia Pacific is set to post
noteworthy CAGR during the forecast period, owing to growing pipeline
molecules and a large number of companies competing in the market.
- Some of the key players in this
market are UniQure N.V, Spark Therapeutics LLC, Bluebird Bio, Juno
Therapeutics, GlaxoSmithKline, Celgene Corporation, Shire Plc, Sangamo
Biosciences, Dimension Therapeutics, Voyager Therapeutics, Human Stem Cell
Institute, Bristol Myer’s Squibb, and Chiesi Farmaceutici S.p.A.
Browse more reports of this category by
Grand View Research: www.grandviewresearch.com/industry/biotechnology
Grand View Research has
segmented the global gene therapy market by indication, vector type, and
region:
Gene Therapy
Indication Outlook (Revenue, USD Million, 2014 - 2026)
- Cancer
- Cardio Vascular Diseases
- Infectious Diseases
- Genetic Disorders
- Neuro Disorders
- Others
Gene Therapy Vector
Type Outlook (Revenue, USD Million, 2014 - 2026)
- Viral Vectors
- Retrovirus
- Adenovirus
- Adeno-associated virus
- Vaccinia virus
- Herpes simplex virus
- Others
- Non-Viral Vectors
- Injection of Naked DNA
- Lipofection
- Others
Gene
Therapy Regional Outlook (Revenue, USD Million, 2014 - 2026)
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- Asia Pacific
- China
- Japan
- Latin America
- Brazil
- MEA
- South Africa
Browse press release of this report by
Grand View Research: www.grandviewresearch.com/press-release/global-gene-therapy-market
About Grand View Research
Grand View Research,
Inc. is a U.S. based market research and consulting company, registered in the
State of California and headquartered in San Francisco. The company
provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For
more information: www.grandviewresearch.com
No comments:
Post a Comment